Lanreotide in the Treatment of Small Bowel Motility Disorders
Status:
Completed
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
This is a human research study looking at the effectiveness of Lanreotide (study medication)
in treating small bowel motility disorders. It is similar to a natural hormone somatostatin
that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a
growth hormone-inhibiting hormone. Lanreotide is a man made hormone and is a long acting
medication that is given once a month. It is marketed with a trade name "Somatuline Depot".
It is given deep subcutaneously (deep within the layers of the skin) in the superior external
quadrant of the buttock. Injection site will be alternated on subsequent injections.